Alibaba Health stock holds a Buy consensus at HKD 4.53

Published on 10/08/2026 at 03:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Fifteen analysts give Alibaba Health stock a Buy consensus as of October 7, 2026. The shares traded at HKD 2.83 on October 8, 2026.

Alibaba Health, BMG0171K1018, Illustration mit AI erstellt.

Alibaba Health (ISIN BMG0171K1018) stock has an average 12-month analyst target of HKD 4.53, while Investing.com lists 15 analysts and an overall Buy consensus as of October 7, 2026. The reported target implies 60.51 percent upside in the published consensus view.

Fifteen analysts split the view

The consensus consists of 10 Buy ratings, 3 Hold ratings and 2 Sell ratings, according to Investing.com. Its published target range runs from HKD 2.79995318 to HKD 8.00070233, a wide spread that signals sharply different assumptions about Alibaba Health's earnings path.

Regulation weighs on forecasts

On October 2, CLSA cut its target for Alibaba Health from HKD 4.70 to HKD 3.70 and retained an Outperform rating, as Investing.com reported. The report said management reduced fiscal 2027 revenue growth guidance from 10 percent to 15 percent to 7 percent to 10 percent because of weaker nutrition-product sales, subsidy reductions and regulatory pressure.

The same October 2 report said Alibaba Health expected nutrition-product sales to recover to year-over-year growth in the second half of fiscal 2027 as merchants adapt to new rules. Pharmaceutical sales were described as maintaining high-teens growth in the first half, creating a split between the company's core drug business and more pressured non-drug categories.

Digital health remains a second pillar

Investing.com describes Alibaba Health as an investment holding company active in pharmaceutical direct sales, pharmaceutical e-commerce, healthcare services and digital businesses. That mix matters for the valuation debate because drug demand supports the near-term operating case, while medical AI and digital services require continued investment before they can materially offset weaker health-product sales.

The company's investor-relations calendar lists May 15, 2026 as the announcement date for its fiscal year 2026 annual results, according to Alibaba Health. The next valuation checkpoint is therefore the balance between pharmaceutical growth, nutrition-product recovery and spending on medical AI.

Stock sits 2.91 percent above yearly low

Alibaba Health was trading at HKD 2.83 on the Hong Kong Stock Exchange on October 8, 2026 at 9:29 a.m. HKT, up HKD 0.01 or 0.35 percent from HKD 2.82. The session range was HKD 2.81 to HKD 2.88, volume reached 24,752,677 shares and market capitalization stood at HKD 45.8 billion.

The stock's 52-week range was HKD 2.75 to HKD 7.91, leaving the October 8 price 2.91 percent above the yearly low. That market position contrasts with the HKD 4.53 consensus target and keeps forecast revisions, rather than the headline rating label alone, central to the investment case.